Study of NI-071 in Comparison With Remicade in Patients With Rheumatoid Arthritis

Inclusion criteria

• Diagnosis of Rheumatoid Arthritis (RA) as defined by the 1987 revised American College of Rheumatology (ACR) criteria with ACR Functional Classification class I-III and disease duration of no less than 3 months
• Patients must receive a minimum of 3 months treatment with methotrexate (MTX) (≥ 6 mg/week) prior to the Screening Visit. Patients must be on a stable dose of MTX (6 mg~16 mg mg/week) for a minimum of 4 weeks prior to the Screening Visit

Exclusion criteria

• History of following diseases

• Other Connective tissue disorders with joint symptom which may interfere the efficacy assessment
• Chlonic or recurrent infectious disease（bronchial ectasia, sinus inflammation etc.）
• Severe infectious disease（hepatitis, pneumonia、sepsis）
• History of demyelinating disease or multiple sclerosis
• Congestive heart failure
• lymphoproliferative disorder or myelodysplastic syndrome
• History of malignancy
• Interstitial lung disease
• Patients with active or latent tuberculosis or history of tuberculosis